Rho kinase inhibition ameliorates vascular remodeling and blood pressure elevations in a rat model of apatinib-induced hypertension
Authors:
Open Access
- 2 December 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 40 (4) , 675-684
Abstract
Objectives: Hypertension is one of the major adverse effects of tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factors. However, the mechanism underlying TKIs-induced hypertension remains unclear. Here, we explored the role of the RhoA/Rho kinase (ROCK) signaling pathway in elevation of blood pressure (BP) induced by apatinib, a selective TKI approved in China for treatment of advanced or metastatic gastric cancer. A nonspecific ROCK inhibitor, Y27632, was then combined with apatinib and its efficacy in alleviating apatinib-induced hypertension was evaluated. Methods: Normotensive female Wistar–Kyoto rats were exposed to two different doses of apatinib, or apatinib combined with Y27632, or vehicle for 2 weeks. BP was monitored by a tail-cuff plethysmography system. The mRNA levels and protein expression in the RhoA/ROCK pathway were determined, and vascular remodeling assessed. Results: Administration of either a high or low dose of apatinib was associated with a rapid rise in BP, reaching a plateau after 12 days. Apatinib treatment mediated upregulation of RhoA and ROCK II in the mid-aorta, more significant in the high-dose group. However, ROCK I expression showed no statistically significant differences. Furthermore, the mRNA level of GRAF3 decreased dose-dependently. Apatinib administration was also associated with decreased levels of MLCP, and elevated endothelin-1 (ET-1) and collagen I, which were accompanied with increased mid-aortic media. However, treatment with Y27632 attenuated the above changes. Conclusion: These findings suggest that activation of the RhoA/ROCK signaling pathway could be the underlying mechanism of apatinib-induced hypertension, while ROCK inhibitor have potential therapeutic value.Keywords
This publication has 56 references indexed in Scilit:
- Mechanism of hypertension and proteinuria during angiogenesis inhibitionJournal Of Hypertension, 2013
- Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertensionCardiovascular Research, 2012
- The Vascular Endothelial Growth Factor Receptor Inhibitor Sunitinib Causes a Preeclampsia-Like Syndrome With Activation of the Endothelin SystemHypertension, 2011
- Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 LevelsHypertension, 2010
- The role of Rho protein signaling in hypertensionNature Reviews Cardiology, 2010
- Impaired Autonomic Regulation of Resistance Arteries in Mice With Low Vascular Endothelial Growth Factor or Upon Vascular Endothelial Growth Factor Trap DeliveryCirculation, 2010
- ROCK Isoform Regulation of Myosin Phosphatase and Contractility in Vascular Smooth Muscle CellsCirculation Research, 2009
- Elevated Endothelin-1 Levels Impair Nitric Oxide Homeostasis Through a PKC-Dependent PathwayCirculation, 2006
- In Vivo Evidence of an Endothelin-Induced Vasopressor Tone After Inhibition of Nitric Oxide Synthesis in RatsCirculation, 1995
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988